L. Hendriks

MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion

C. Dooms, D. de Ruysscher, A. Dingemans, 2018, Journal of Thoracic Oncology.

MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts

N. Girard, H. Gietema, G. Scagliotti, 2018, Journal of Thoracic Oncology.

MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC

N. Girard, A. Dingemans, S. Lantuejoul, 2018, Journal of Thoracic Oncology.

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

T. Mok, G. Veronesi, D. Planchard, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

127P Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?

H. Gietema, S. Keek, H. Woodruff, 2022, Annals of Oncology.

Malignant Pleural Mesothelioma: new guidelines make us stronger for defeating this disease.

P. Bironzo, J. Remon, L. Hendriks, 2021, Annals of Oncology.

OA06.05 Consensual Definition of Stage III NSCLC Resectability: EORTC-Lung Cancer Group Initiative with Other Scientific Societies

A. Dingemans, C. Faivre-Finn, M. Guckenberger, 2023, Journal of Thoracic Oncology.